235 related articles for article (PubMed ID: 37843627)
1. Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.
Assi T; Ngo C; Faron M; Verret B; Lévy A; Honoré C; Hénon C; Le Péchoux C; Bahleda R; Le Cesne A
Curr Treat Options Oncol; 2023 Nov; 24(11):1598-1613. PubMed ID: 37843627
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
3. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
[TBL] [Abstract][Full Text] [Related]
4. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
Langmans C; Cornillie J; van Cann T; Wozniak A; Hompes D; Sciot R; Debiec-Rychter M; Vandenbempt I; Schöffski P
Oncol Res Treat; 2019; 42(7-8):396-404. PubMed ID: 31170709
[TBL] [Abstract][Full Text] [Related]
6. The importance of treating by histological subtype in advanced soft tissue sarcoma.
Martín Broto J; Le Cesne A; Reichardt P
Future Oncol; 2017 Jan; 13(1s):23-31. PubMed ID: 27918201
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Suarez-Kelly LP; Baldi GG; Gronchi A
Expert Opin Pharmacother; 2019 Aug; 20(12):1503-1515. PubMed ID: 31136210
[No Abstract] [Full Text] [Related]
8. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?
Blay JY
Future Oncol; 2019 Sep; 15(26s):5-10. PubMed ID: 31500446
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model.
Kiyuna T; Tome Y; Murakami T; Kawaguchi K; Igarashi K; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Russell TA; Elliott I; Singh SR; Kanaya F; Eilber FC; Hoffman RM
BMC Cancer; 2018 Aug; 18(1):840. PubMed ID: 30126369
[TBL] [Abstract][Full Text] [Related]
13. Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.
Mochizuki T; Ikegami M; Akiyama T
Cancer Sci; 2024 Feb; 115(2):575-588. PubMed ID: 38115234
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Italiano A; Toulmonde M; Bui-Nguyen B
Bull Cancer; 2010 Jun; 97(6):679-86. PubMed ID: 20483708
[TBL] [Abstract][Full Text] [Related]
15. Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma.
Kiyuna T; Tome Y; Murakami T; Zhao M; Miyake K; Igarashi K; Kawaguchi K; Miyake M; Oshiro H; Higuchi T; Li Y; Dry SM; Nelson SD; Russell TA; Eckardt MA; Singh AS; Kanaya F; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Sep; 119(9):7827-7833. PubMed ID: 29932244
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ratan R; Patel SR
Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
[TBL] [Abstract][Full Text] [Related]
17. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin for metastatic liposarcoma and leiomyosarcoma: Comparison of real-world experience in an Australian sarcoma specialist center to pivotal clinical trial results.
Zhou DD; King D; Thomson K; Grimison P
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e526-e528. PubMed ID: 35297193
[No Abstract] [Full Text] [Related]
19. Chemotherapy With Eribulin Following Potentially Curative Surgery in Patients With Localized Liposarcoma.
Steinbrecher O; Brodowicz T; Popov P; Lamm W
In Vivo; 2024; 38(1):385-389. PubMed ID: 38148100
[TBL] [Abstract][Full Text] [Related]
20. Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report.
Matsuda S; Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
Medicine (Baltimore); 2020 Jan; 99(2):e18689. PubMed ID: 31914068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
